Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:26:45 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:TGTX - TG THERAPEUTICS INC - https://www.tgtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TGTX - Q5.027.01·29.246.028.86+1.104.01,621.745,65913,37928.25  28.95  27.8346.48  25.2819:43:4607:3015 min RT 2¢

Recent Trades - Last 10 of 13379
Time ETExPriceChangeVolume
19:43:46Q27.82560.0656500
18:40:44Q29.001.244
17:55:51Q29.001.241
17:48:27Q28.951.1910
17:37:27Q28.861.1046,827
16:54:55Q28.901.1412
16:52:50Q28.710.951
16:52:49Q28.761.002
16:45:25Q28.981.2250
16:20:00Q28.861.10249

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2026-01-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2026-01-13 16:25U:TGTXNews ReleaseTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
2026-01-07 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-28 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-19 08:30U:TGTXNews ReleaseTG Therapeutics Makes 2025 Deloitte Technology Fast 500(TM) List of America's Fastest-Growing Companies
2025-11-10 16:00U:TGTXNews ReleaseTG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
2025-11-03 07:00U:TGTXNews ReleaseTG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-10-31 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
2025-10-28 07:30U:TGTXNews ReleaseTG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
2025-09-24 09:10U:TGTXNews ReleaseNew Data for BRIUMVI(TM) Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
2025-09-10 07:31U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2025-09-08 07:30U:TGTXNews ReleaseTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
2025-09-04 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-03 07:30U:TGTXNews ReleaseTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
2025-08-28 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Cantor Global Healthcare Conference
2025-08-04 07:00U:TGTXNews ReleaseTG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
2025-07-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
2025-06-06 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-06-02 08:00U:TGTXNews ReleaseTG Therapeutics to Participate in the Jefferies Global Healthcare Conference